Obesity drug maker Sciwind targets IPO, with heavyweight backers
腾讯美团押注减肥药明星企业 先为达生物冲刺港股

Supported by Tencent and Meituan, the biotech aims to launch a targeted GLP-1 drug next year that could challenge established products, but it faces stiff competition
核心产品埃诺格鲁肽注射液预计将于2026年正式获批上市，公司已处于商业化前夕。